IL212447A - Composition with extended release containing 2-oxo-1-pyrrolidine sequels - Google Patents

Composition with extended release containing 2-oxo-1-pyrrolidine sequels

Info

Publication number
IL212447A
IL212447A IL212447A IL21244711A IL212447A IL 212447 A IL212447 A IL 212447A IL 212447 A IL212447 A IL 212447A IL 21244711 A IL21244711 A IL 21244711A IL 212447 A IL212447 A IL 212447A
Authority
IL
Israel
Prior art keywords
oxo
release formulations
prolonged release
pyrrolidine derivative
pyrrolidine
Prior art date
Application number
IL212447A
Other languages
English (en)
Hebrew (he)
Other versions
IL212447A0 (en
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of IL212447A0 publication Critical patent/IL212447A0/en
Publication of IL212447A publication Critical patent/IL212447A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL212447A 2008-11-18 2011-04-26 Composition with extended release containing 2-oxo-1-pyrrolidine sequels IL212447A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08105817 2008-11-18
EP09100312 2009-06-02
PCT/EP2009/065271 WO2010057870A1 (en) 2008-11-18 2009-11-17 Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative

Publications (2)

Publication Number Publication Date
IL212447A0 IL212447A0 (en) 2011-06-30
IL212447A true IL212447A (en) 2016-10-31

Family

ID=41381618

Family Applications (1)

Application Number Title Priority Date Filing Date
IL212447A IL212447A (en) 2008-11-18 2011-04-26 Composition with extended release containing 2-oxo-1-pyrrolidine sequels

Country Status (17)

Country Link
US (3) US10172805B2 (enExample)
EP (1) EP2358360B1 (enExample)
JP (2) JP5954890B2 (enExample)
KR (1) KR101689688B1 (enExample)
CN (2) CN102215829B (enExample)
AU (1) AU2009317280B2 (enExample)
BR (1) BRPI0921313A2 (enExample)
CA (1) CA2741041C (enExample)
DK (1) DK2358360T3 (enExample)
EA (1) EA019572B1 (enExample)
ES (1) ES2602604T3 (enExample)
HU (1) HUE032275T2 (enExample)
IL (1) IL212447A (enExample)
MX (1) MX339852B (enExample)
PL (1) PL2358360T3 (enExample)
PT (1) PT2358360T (enExample)
WO (1) WO2010057870A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2346500B1 (en) 2008-10-16 2017-05-17 The Johns Hopkins University Methods and compositions for improving cognitive function
KR101689688B1 (ko) * 2008-11-18 2016-12-26 유씨비 파마, 에스.에이. 2­옥소­1­피롤리딘 유도체를 포함하는 지연 방출형 제형
WO2011107855A2 (en) * 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
EP2563339A1 (en) * 2010-04-29 2013-03-06 Lupin Limited Controlled release pharmaceutical compositions of brivaracetam
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
EP3127539A1 (en) * 2015-08-03 2017-02-08 Latvian Institute Of Organic Synthesis Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN111407738A (zh) * 2020-04-03 2020-07-14 江苏艾立康药业股份有限公司 一种布立西坦控释制剂及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6327424A (ja) 1986-07-17 1988-02-05 Shionogi & Co Ltd 徐放性製剤およびその製造法
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5622716A (en) 1987-02-20 1997-04-22 Farmarc Nederland B.V. Process for preparing a retard product containing diltiazem for a single daily administration
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
EP0452862B1 (en) * 1990-04-18 1995-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Spherical seed cores, spherical granules and process for production thereof
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
JPH10182438A (ja) * 1991-03-07 1998-07-07 Takeda Chem Ind Ltd 有核散剤
DE19630035A1 (de) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
ZA200505180B (en) 2002-11-28 2006-10-25 Themis Lab Private Ltd Process for manufacturing sustained release microbeads containing venlafaxine HCI
DE10353186A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
WO2006088864A1 (en) 2005-02-16 2006-08-24 Elan Pharma International Limited Controlled release compositions comprising levetiracetam
CA2600282A1 (en) * 2005-03-29 2006-10-05 Roehm Gmbh Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
WO2006125074A1 (en) * 2005-05-17 2006-11-23 Brown University Research Foundation Drug delivery formulations for targeted delivery
US20070264346A1 (en) * 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
FR2897267A1 (fr) 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
EP2041084B1 (en) 2006-06-08 2013-11-06 UCB Pharma, S.A. Co-crystals of pyrrolidinones
DE102006035549A1 (de) * 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
NZ575171A (en) * 2006-08-31 2012-04-27 Aptalis Pharmatech Inc Drug delivery systems comprising solid solutions of weakly basic drugs
CN101801356B (zh) * 2007-09-21 2016-10-19 赢创罗姆有限公司 耐受乙醇影响的非阿片类的pH依赖性受控释放的药物组合物
WO2009102964A2 (en) * 2008-02-14 2009-08-20 Nordson Corporation Apparatus for testing containers, tray for holding cylinders and suction-basedchuck for robotic arm
KR101788804B1 (ko) * 2008-11-18 2017-10-20 유씨비 파마, 에스.에이. 2―옥소―1―피롤리딘 유도체를 포함하는 연장 방출 제형
KR101689688B1 (ko) * 2008-11-18 2016-12-26 유씨비 파마, 에스.에이. 2­옥소­1­피롤리딘 유도체를 포함하는 지연 방출형 제형

Also Published As

Publication number Publication date
CA2741041C (en) 2015-01-13
IL212447A0 (en) 2011-06-30
BRPI0921313A2 (pt) 2015-12-29
MX339852B (es) 2016-06-15
CA2741041A1 (en) 2010-05-27
HK1159503A1 (en) 2012-08-03
JP2015120756A (ja) 2015-07-02
DK2358360T3 (en) 2016-12-12
ES2602604T3 (es) 2017-02-21
EP2358360A1 (en) 2011-08-24
PT2358360T (pt) 2016-11-15
PL2358360T3 (pl) 2017-02-28
AU2009317280A1 (en) 2010-05-27
AU2009317280B2 (en) 2014-03-06
US20200085754A1 (en) 2020-03-19
KR20110089182A (ko) 2011-08-04
WO2010057870A1 (en) 2010-05-27
HUE032275T2 (en) 2017-09-28
EA019572B1 (ru) 2014-04-30
CN102215829A (zh) 2011-10-12
MX2011004816A (es) 2011-05-30
EA201100752A1 (ru) 2012-01-30
US20190142759A1 (en) 2019-05-16
JP2012509357A (ja) 2012-04-19
JP5954890B2 (ja) 2016-07-20
KR101689688B1 (ko) 2016-12-26
CN104208714A (zh) 2014-12-17
CN102215829B (zh) 2014-12-10
US20110250282A1 (en) 2011-10-13
EP2358360B1 (en) 2016-09-14
US10172805B2 (en) 2019-01-08

Similar Documents

Publication Publication Date Title
IL212447A0 (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative
IL198168A0 (en) Robust sustained release formulations
IL217153A0 (en) Controlled release formulations
GB0815435D0 (en) Formulations
IL211231A0 (en) Sustained release formulations using non-aqueous carriers
GB2459691B (en) Formulations
IL211028A0 (en) Linaclotide-containing formulations for oral administration
GB0823269D0 (en) Formulations
GB0821789D0 (en) Formulations
IL212271A (en) Elongated release vehicles containing 2-oxo-1-pyrrolidine
ZA201100635B (en) Sustained release pharmaceutical compositions comprising quetiapine
EP2307021A4 (en) FORMULATIONS
HUE026592T2 (hu) Növényvédelmi készítmények
IL213559A0 (en) Oral formulations
EP2296709A4 (en) NIACIN FORMULATIONS WITH MODIFIED RELEASE
ZA201100923B (en) Pyrazolone derivative formulations
GB0921378D0 (en) Formulations
GB0916030D0 (en) Formulations
GB0822171D0 (en) Temisartan formulations
ZA200902096B (en) Robust sustained release formulations
GB0817079D0 (en) Formulations
GB0916106D0 (en) Formulations
GB0811447D0 (en) Formulations
GB0807906D0 (en) Formulations
GB0823493D0 (en) Formulations

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed